Global Biosimilars Market - Forecasts From 2018 to 2023

November 2018 | 110 pages | ID: G14ACBD09A1EN
Knowledge Sourcing Intelligence LLP

Abstracts

The global biosimilar market is estimated to register a CAGR of 40.14% over the forecast period of to reach a market size of US$19.151 billion by 2023 from US$2.528 billion in 2017. Biosimilars are defined as the licensed and highly similar version of biologic drugs that have already been approved for use by the regulatory bodies. The growth in the market may be attributed to the cost-effectiveness of the biosimilars when compared to reference biologics coupled with the patent expiration of the many blockbuster biologic drugs. By 2018, biologics worth more than US$68 billion annual sales will lose patent protection. Estimated patent and exclusivity expiry of few of the blockbuster biologics are given below. Due to structural complexity of the biosimilar drugs, multi-layered manufacturing and risk of immunogenicity, separate regulatory pathways have been drafted to introduce them into the market.
Increasing investment by the companies for the development of biosimilars will also be the key factor driving the market. Recently in August 2018, Stada, a German biopharmaceutical company announced the investment of $ 115 million n biosimilar development by becoming a major shareholder in BioCeuticals, a venture capital-funded organization created by Stada to carry out its biosimilar programs. Similarly, Merck, in February 2018, invested $49 million to support the growing demand with new biopharmaceutical manufacturing and distribution centers in South Korea and India, while accelerating biosimilars manufacturing and development in China. Thus, growing interest of the companies towards biosimilars will augment the market during the given time frame. New drug launches and collaborations have also helped the companies and bolstered the market. For instance, in January 2018, Biocon and Sandoz entered into a strategic partnership to develop the next generation of biosimilars in immunology and cancer. However, stringent regulations for the development and production of biosimilars could hinder biosimilars market growth.
Geographically, Europe holds the largest market share due to the presence of well-known biopharmaceutical companies such as Stada, Sandoz, AstraZeneca, Merck etc. Also well-defined regulatory framework for the approval of biosimilars and rising number of product approvals coupled with well-developed healthcare infrastructure have further provided a boost to the European biosimilar market. Similarly, North America will also show robust growth during the forecast period owing to the increasing focus on the product development coupled with the rising efforts from the manufacturers to tap the growth opportunities in the region.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global biosimilar market.

Major industry players profiled as part of the report are Sandoz, Stada Arzneimittel, Dr. Reddy's Laboratories, Biocad and Samsung Bioepis among others.

Segmentation

By Type
Monoclonal antibodies
Recombinant Proteins
Hormones
Others
By Disease
Infectious Disease
Oncology and Immunology
Respiratory
Genetic Disorders
Others
By Geography
North America
US
Canada
Others
South America
Brazil
Argentina
Others
Europe
UK
Germany
France
Others
Middle East and Africa
Asia Pacific
China
India
Australia
Japan
Others

Contents

1. INTRODUCTION

1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Secondary Sources
2.3. Validation

3. KEY FINDINGS OF THE STUDY

4. MARKET DYNAMICS

4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Porter’s Five Forces Analysis
  4.5.1. Bargaining Power of Suppliers
  4.5.2. Bargaining Power of Buyers
  4.5.3. Threat of New Entrants
  4.5.4. Threat of Substitutes
  4.5.5. Competitive Rivalry in the Industry
4.6. Industry Value Chain Analysis
4.7. Industry Regulations
4.8. Scenario Analysis

5. GLOBAL BIOSIMILARS MARKET FORECAST BY TYPE

5.1. Monoclonal Antibodies
5.2. Recombinant Proteins
5.3. Hormones
5.4. Others

6. GLOBAL BIOSIMILARS MARKET FORECAST BY DISEASE

6.1. Infectious Disease
6.2. Oncology and Immunology
6.3. Respiratory
6.4. Genetic Disorders
6.5. Others

7. GLOBAL BIOSIMILARS MARKET FORECAST BY GEOGRAPHY

7.1. North America
  7.1.1. The U.S
  7.1.2. Canada
  7.1.3. Mexico
  7.1.4. Others
7.2. South America
  7.2.1. Brazil
  7.2.2. Argentina
  7.2.3. Others
7.3. Europe
  7.3.1. U.K.
  7.3.2. France
  7.3.3. Germany
  7.3.4. Italy
  7.3.5. Others
7.4. Middle East and Africa
7.5. Asia Pacific
  7.5.1. China
  7.5.2. India
  7.5.3. Australia
  7.5.4. Japan
  7.5.5. Others

8. COMPETITIVE INTELLIGENCE

8.1. Market Share Analysis
8.2. Strategies of Key Players
8.3. Recent Investments and Deals

9. COMPANY PROFILES

9.1. Samsung Bioepis
  9.1.1. Overview
  9.1.2. Financials
  9.1.3. Product and Services
  9.1.4. Recent Development
9.2. Stada Arzneimittel AG
  9.2.1. Overview
  9.2.2. Financials
  9.2.3. Product and Services
  9.2.4. Recent Development
9.3. Sandoz International GmbH (A Novartis Company)
  9.3.1. Overview
  9.3.2. Financials
  9.3.3. Product and Services
  9.3.4. Recent Development
9.4. Amgen Inc.
  9.4.1. Overview
  9.4.2. Financials
  9.4.3. Product and Services
  9.4.4. Recent Development
9.5. Apotex Inc.
  9.5.1. Overview
  9.5.2. Financials
  9.5.3. Product and Services
  9.5.4. Recent Development
9.6. BioCad
  9.6.1. Overview
  9.6.2. Financials
  9.6.3. Product and Services
  9.6.4. Recent Development
9.7. Dr. Reddy’s Laboratories Ltd.
  9.7.1. Overview
  9.7.2. Financials
  9.7.3. Product and Services
  9.7.4. Recent Development
9.8. Biocon
  9.8.1. Overview
  9.8.2. Financials
  9.8.3. Product and Services
  9.8.4. Recent Development
9.9. Boehringer Ingelheim International GmbH
  9.9.1. Overview
  9.9.2. Financials
  9.9.3. Product and Services
  9.9.4. Recent Development
9.10. Cinfa Biotech
  9.10.1. Overview
  9.10.2. Financials
  9.10.3. Product and Services
  9.10.4. Recent Development
9.11. Biogen International
  9.11.1. Overview
  9.11.2. Financials
  9.11.3. Product and Services
  9.11.4. Recent Development
9.12. Hospira (A Pfizer Company)
  9.12.1. Overview
  9.12.2. Financials
  9.12.3. Product and Services
  9.12.4. Recent Development
List of Tables
List of Figures